Source link : https://www.newshealth.biz/health-news/novel-anti-inflammatory-flops-for-hfpef-hfmref/
CHICAGO — The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF), the phase II ENDEAVOR trial showed. For the primary endpoint of Kansas City Cardiomyopathy Questionnaire (KCCQ-TSS) quality of life scores, the drug had only a -1.4 point […]
Author : News Health
Publish date : 2024-11-18 21:49:42
Copyright for syndicated content belongs to the linked Source.